Industry insights, all in one place.

Millions of people with diabetes never receive a timely retinal exam — not for lack of technology, but for lack of access. Autonomous AI is changing that by bringing clinical-grade screening directly to primary care.

May 1, 2026

Not all AI diagnostics are equal. FDA clearance for autonomous operation means the evidence has been independently reviewed and the system is safe to deliver results without a clinician in the loop.

April 15, 2026

Primary care visits are the single best opportunity to screen patients with diabetes for retinopathy. Here's how autonomous AI integrates into the workflow — and what happens when a positive result comes back.

April 1, 2026

Black, Hispanic, and low-income populations carry a disproportionate burden of diabetic retinopathy. Autonomous AI screening removes the referral barriers that have long made equity in eye care an unfulfilled promise.

March 15, 2026

Diabetic retinopathy causes no symptoms until it is often too late to prevent vision loss. Understanding the four stages of the disease — and why early detection matters — is the first step toward better outcomes.

March 1, 2026

Autonomous AI retinal screening is reimbursable, staff-operable, and documented to reduce downstream treatment costs. Here is the financial and operational case for adding it to your diabetes care workflow.

February 15, 2026